Moderna has started a clinical trial for an experimental mRNA vaccine designed to prevent Lyme disease, enrolling about 350 healthy adults aged 18 to 70 in a randomized, placebo-controlled study. The trial will monitor safety and measure immune responses to assess whether the vaccine can protect against infection. The study is registered as NCT07561294 and is running across multiple sites in Canada and the U.S.-adjacent region. Moderna’s entry highlights continued investment in mRNA platforms for infectious disease prevention beyond established respiratory targets.